[Asia Economy Reporter Hyunseok Yoo] Gold Pacific is showing strong performance. The news that it is accelerating the development of a novel coronavirus disease (COVID-19) treatment with over 50 times the therapeutic efficacy of 'Remdesivir' appears to have had an impact.
As of 11:05 AM on the 9th, Gold Pacific was trading at 1,665 KRW, up 21.53% (295 KRW) compared to the previous trading day.
On the same day, Gold Pacific announced that its subsidiary APRG acquired the COVID-19 treatment candidate substance 'APRG64,' which is in the clinical stage, from Professor Kang Se-chan of Kyung Hee University.
The development team led by Professor Kang plans to officially begin clinical trials through a consortium composed of companies equipped with raw material pharmaceutical production and finished drug production capabilities, as well as a contract research organization (CRO) to conduct the clinical trials. APRG64 is a new drug candidate substance discovered by Professor Kang Se-chan based on natural products. Professor Kang’s research team started developing APRG64 in May for the treatment of hepatitis C. Based on research results, it was expected to be effective against COVID-19, which is also an RNA virus, and efficacy verification as a treatment was conducted.
Research results indicate that APRG64 has over 50 times the cell entry blocking and post-infection proliferation inhibition effects compared to Remdesivir, the first COVID-19 treatment approved by the U.S. Food and Drug Administration (FDA). APRG64 is evaluated as a better treatment candidate than currently developed therapeutics because it can prevent COVID-19 infection and treat it after infection. A patent application for APRG64 as a COVID-19 treatment has also been completed.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
